Lipid-altering compositions for the treatment of infertility
AssigneeMassachusetts Institute of Technology
InventorsMonty Krieger, Helena E. Miettinen
Life of this patent
Estimating the term…
Loading patent…
AssigneeMassachusetts Institute of Technology
InventorsMonty Krieger, Helena E. Miettinen
Estimating the term…
SR-BI is present at relatively high levels on the membranes of hepatocytes and steroidogenic tissues, including the adrenal gland, testes, and ovaries, where it mediates the uptake and transport of cholesteryl ester from high density lipoproteins. It has been demonstrated that transgenic animals which do not produce SR-BI are healthy, with the exception that the females are infertile. SR-BI KO females have abnormal HDLs, ovulate dysfunctional oocytes and are infertile. Surgical, genetic and pharmacologic methods were used to show that the fertility of SR-BI KO females (or their transplanted oocytes) can be restored in the absence of ovarian and/or extraovarian SR-BI expression by manipulations that modify the structure, composition and/or abundance of their abnormal plasma lipoproteins. These manipulations included inactivation of the apolipoprotein A-I gene and administration of the cholesterol-lowering drug PROBUCOL™. In the absence of treatment, female animals which do not express SR-BI have dramatically reduced levels of offspring, even though they are otherwise healthy and the males normal. Studies demonstrate that they do not produce viable eggs and have a defect involving implantation of normal eggs.
A method for treating infertility or reproductive disorders involving abnormal levels of lipids in a mammal comprising administering a compound altering directly or indirectly the transfer of cholesterol or cholesteryl ester from high density lipoprotein or other lipoproteins via SR-BI to liver or steroidogenic tissues or compounds blocking oxidative modification of LDL.
Dependencies are inferred from the claim text.